Welcome to our dedicated page for ProQR Therapeutics N.V. SEC filings (Ticker: PRQR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ProQR Therapeutics N.V. filings document a Nasdaq-listed foreign private issuer furnishing Form 6-K current reports for its RNA therapeutics business. The disclosures describe the Axiomer RNA editing platform, ADAR-mediated oligonucleotide design, pipeline programs including AX-0810, AX-2402 and AX-2911, scientific presentations, collaborations, and annual operating and financial results.
The filing record also covers governance and capital-market matters, including annual general meeting notices, agenda materials, proxy forms, proposed articles-of-association amendments, board nominations and board-composition updates. Several Form 6-K reports incorporate company materials by reference into Form F-3 registration statements, linking current business updates with registered securities disclosure.
ProQR Therapeutics N.V. (PRQR) reported that the first participant has been dosed in its Phase 1 clinical trial of AX-0811, an AI-discovered investigational RNA editing oligonucleotide designed to modulate NTCP as a potential disease-modifying treatment for cholestatic liver diseases, including biliary atresia. The study in healthy volunteers will assess safety, tolerability, pharmacokinetics and pharmacodynamic biomarkers and builds on prior clinical experience with AX-0810, with initial Phase 1 target engagement data from the first two cohorts expected in early January 2027.
ProQR also plans a virtual Investor and Analyst educational event titled “NTCP Modulation in Biliary Atresia via Liver-Targeted RNA Editing” on September 30, 2026 at 11 a.m. ET, featuring company management and Professor Gideon Hirschfield to review AX-0810 Phase 1 data and outline the clinical development strategy for NTCP modulation in biliary atresia.
ProQR Therapeutics N.V. reported second-quarter and first-half 2026 results and detailed recent financing and pipeline progress. For the quarter ended June 30, 2026, revenue was €8.8 million, up from €3.8 million a year earlier, primarily from its collaboration with Eli Lilly. Net loss for the quarter narrowed to €8.7 million, or €0.08 per share, compared with a loss of €12.2 million, or €0.12 per share, in 2025, as operating expenses grew modestly while revenue more than doubled.
Cash and cash equivalents were €117.1 million at June 30, 2026, up from €92.4 million at December 31, 2025, supported by a June underwritten registered direct offering and concurrent private placement raising gross proceeds of about $59.2 million. Management states this provides funding runway into mid-2028 and supports advancement of its Axiomer RNA editing pipeline, including AX-0810 and AX-0811 for cholestatic liver diseases and earlier-stage programs in MPS I Hurler syndrome and MASH.
ProQR Therapeutics reported second-quarter 2026 results and highlighted clinical validation of its Axiomer™ RNA editing platform. Phase 1 data for AX-0810 in healthy volunteers showed up to 8‑fold increases in total serum bile acids at 6 mg/kg, exceeding the predefined 2‑fold threshold for meaningful NTCP modulation, with a favorable safety profile and an estimated eight-week half-life. A Phase 1 trial of next-generation NTCP candidate AX-0811 is planned pending CTA authorization, with initial data expected by year-end 2026, and multiple additional programs (biliary atresia IIT, AX-0422, AX-2911) targeted to read out in 2027.
Financially, second-quarter 2026 revenue was €8.8 million, up from €3.8 million a year earlier, and net loss narrowed to €8.7 million from €12.2 million. Cash and cash equivalents increased to €117.1 million at June 30, 2026 from €92.4 million at year-end 2025, supported by a $59.2 million equity financing with public investors and Eli Lilly. Equity rose to €79.5 million, and management states this funding provides cash runway into mid‑2028.
ProQR Therapeutics N.V. reports that Chief Executive Officer Daniel Anton de Boer purchased 200,000 Ordinary Shares on 2026-07-31 at $1.7698 per share in a transaction described as a purchase in open market or private transaction, increasing his direct holdings to 500,000 shares. The Rule 10b5-1 trading-plan checkbox was not marked for this transaction.
Aberdeen Group plc and its affiliate abrdn Inc. report beneficial ownership of 8,932,507 Ordinary Shares of ProQR Therapeutics N.V., representing 6.33% of this class of shares. The securities are Ordinary Shares with a nominal value of EUR0.04 per share.
Both Aberdeen Group plc and abrdn Inc. report no sole voting or dispositive power over these shares, but each reports shared voting power and shared dispositive power over 8,932,507 shares. abrdn Inc. beneficially owns the shares on behalf of underlying clients within its corporate group structure.
Eli Lilly and Company reports beneficial ownership of 21,995,880 ordinary shares of ProQR Therapeutics N.V., representing 15.6% of the outstanding class of ordinary shares with a nominal value of 0.04 EUR per share.
Eli Lilly holds sole voting power and sole dispositive power over all 21,995,880 shares and reports no shared voting or dispositive power. The filing is signed by Christopher Anderson, Vice President - Leader of Corporate Securities and Assistant Corporate Secretary.
ProQR Therapeutics N.V. director Bart Filius purchased 150,000 Ordinary Shares on July 17, 2026 at $1.7195 per share in a transaction described as a purchase in the open market or a private transaction. After this trade, he directly holds 300,000 Ordinary Shares of the company.
ProQR Therapeutics N.V. is registering the resale, from time to time, of up to 3,030,303 ordinary shares previously issued to a selling shareholder under an April 7, 2026 Share Purchase Agreement. The company is not selling shares in this offering and will receive no proceeds from any resale.
The shares trade on Nasdaq under “PRQR”; the last reported price was $1.81 per share on July 2, 2026. Ordinary shares outstanding were 105,362,551 as of March 31, 2026 and are expected to be 141,121,476 after including June 2026 equity issuances; this is a baseline figure, not the amount being offered.
ProQR is a clinical-stage biotechnology company developing RNA editing therapies using its Axiomer platform, with lead liver and CNS programs such as AX-0810 for cholestatic diseases and additional collaborations with Lilly and Ginkgo Bioworks. As of March 31, 2026, cash and cash equivalents were €81,088 thousand against total debt of €15,733 thousand.